Jaguar Health Inc (NASDAQ: JAGX) has come up on our radar quite a bit over the last few trading sessions. With a veterinary treatment coming close to approval, the stock has been flying. However, is this really a strong opportunity, or are we seeing overreactions to news, leading to gains that will soon fizzle? Today, we’ll chat about:
- what JAGX does;
- recent news surrounding its lead veterinary clinical candidate;
- other products in the veterinary pipeline;
- the company’s work in human medicine;
- risks associated with JAGX; and
- whether or not now is a good time to get involved.
What Does JAGX Do?
Jaguar Health is a biotechnology company that focuses on the development of sustainable derived gastrointestinal products for animal health. While the company is focused on animals, that’s not the only area that JAGX serves. In fact, the company also owns Napo Pharmaceuticals, Inc.
Napo Pharmaceuticals is a company that is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace. The company derives its treatments from plants used traditionally in rainforest areas.
Recent News Surrounding The Company’s Lead Veterinary Clinical Candidate
In recent trading sessions, JAGX has been flying for the top following news that was released last Thursday (3/8/2018) that brings the company closer to the commercialization of CanaleviaTM, the company’s lead veterinary clinical candidate.
CanaleviaTM is a treatment designed for chemotherapy-induced diarrhea (CID) in dogs. According to the press release issued Thursday, JAGX has received news that its reasonable expectation of effectiveness technical section is complete for use of CanaleviaTM as a treatment for CID in dogs. This is the second of four technical sections that need to be completed to push the company’s lead veterinary candidate to commercial phases. In a statement, Dr. Michael Guy, DVM, MS, Ph.D., Vice President and Clinical Veterinarian at Jaguar Health, had the following to offer:
Jaguar has now completed two of the four required technical sections of the Company’s application for conditional approval of CanaleviaTM for CID in dogs. With receipt of conditional approval for this indication, we would expect to conduct the commercial launch for CanaleviaTM for CID in dogs in mid-2019.